DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Procrit (Epoetin Alfa) - Current Clinical Trials

 
 



Procrit Related Clinical Trials

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery [Terminated]

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy [Terminated]

Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia [Withdrawn]

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa [Completed]

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease [Completed]

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS [Completed]

A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities. [Completed]

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa [Terminated]

Comparison Among Erythropoietin Stimulating Agents [Completed]

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy [Completed]

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy [Completed]

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations [Withdrawn]

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy [Terminated]

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease [Completed]

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD) [Completed]

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery [Active, not recruiting]

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients [Completed]

Epoetin Alfa for HIV-Associated Neuropathy Trial [Withdrawn]

Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) [Not yet recruiting]

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy. [Completed]

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia [Terminated]

Efficacy Study of Epoetin Alfa in Friedreich Ataxia [Completed]

Optimized Erythropoietin (EPO) Treatment [Recruiting]

Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy [Completed]

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia. [Completed]

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients [Terminated]

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin [Completed]

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin [Completed]

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks [Completed]

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients. [Completed]

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa [Terminated]

Trial of Peg-Interferon Plus Epoetin-Alfa for Treatment of Chronic Hepatitis C Virus Infection [Completed]

Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery [Not yet recruiting]

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy [Terminated]

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer [Terminated]

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [Withdrawn]

Blood Sparing Strategies: Single Shot High Dose Erythropoietin Two Days Before Heart Surgery [Completed]

A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT) [Completed]

Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia [Completed]

Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia [Completed]

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis [Terminated]

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. [Terminated]

PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects. [Not yet recruiting]

PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects [Not yet recruiting]

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa [Completed]

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. [Completed]

Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients [Recruiting]

Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure [Completed]

PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects [Not yet recruiting]

Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis [Completed]

PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects. [Not yet recruiting]

An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy [Terminated]

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin [Completed]

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin [Completed]

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study) [Completed]

Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) [Active, not recruiting]

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer [Terminated]

Treatment With Erythropoietin and Cognition During Hypoglycaemia [Completed]

Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction [Completed]

Efficacy Study of Two Formulations of Erythropoietin [Completed]

Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder [Completed]

A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies [Withdrawn]

Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients [Completed]

Renal Effects of Erythropoietin in Humans [Completed]

Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human [Recruiting]

Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) [Completed]

Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation [Terminated]

Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD) [Terminated]

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2) [Completed]

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks [Completed]

A Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis [Recruiting]

Erythropoietin Therapy for Children With Cerebral Palsy [Not yet recruiting]

Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI [Not yet recruiting]

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer [Completed]

Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant [Completed]

Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy [Completed]

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes [Active, not recruiting]

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants [Completed]

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients [Terminated]

Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery [Enrolling by invitation]

Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury [Completed]

Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia [Recruiting]

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial [Terminated]

Erythropoietin in Traumatic Brain Injury (EPO-TBI) [Completed]

Dynepo Long-Term Safety Study [Terminated]

Erythropoietin in the Prevention of Acute Mountain Sickness [Completed]

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes [Active, not recruiting]

Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial [Completed]

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia [Completed]

Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity [Completed]

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017